Welcome to our dedicated page for Inari Medical news (Ticker: NARI), a resource for investors and traders seeking the latest updates and insights on Inari Medical stock.
Inari Medical, Inc. (NASDAQ: NARI) is a leading medical device company dedicated to developing innovative solutions for the interventional treatment of vascular thrombi and emboli. The company's mission centers on improving the lives of patients suffering from venous and other related diseases through the design and production of advanced medical devices.
Inari Medical's product portfolio includes several key devices:
- ClotTriever: Designed for the removal of clots from peripheral blood vessels, primarily treating patients with deep vein thrombosis (DVT).
- FlowTriever System: Used for the treatment of pulmonary embolism (PE).
- InThrill System: Aimed at treating small vessel thrombosis.
- LimFlow System: Another innovative solution recently added to their portfolio through acquisition.
The company operates extensively within the United States but also generates significant revenue from international markets. Inari Medical's dedication to clinical research and patient education is evident in their continuous efforts to generate high-quality clinical data to support their products.
In recent news, Inari Medical announced the PEERLESS II RCT, a major clinical study involving up to 1,200 patients. This study aims to influence global guidelines for treating intermediate-risk PE patients. Inari's fourth-quarter financial results showed a substantial revenue increase, driven by the strong adoption of their procedures, new product launches, and global commercial expansion. The company reported $132.1 million in revenue for Q4 2023, marking a 22.6% increase year-over-year.
Additionally, Inari Medical has undertaken significant legal action to protect its intellectual property. The company filed a patent infringement lawsuit against Imperative Care, Inc. and Truvic Medical, Inc., seeking injunctive relief and damages for infringement on eight of its patents.
Guided by principles such as putting patients first and fostering innovation, Inari Medical continues to advance its mission of establishing its treatments as the standard of care for venous thromboembolism and beyond.
Inari Medical, Inc. (NASDAQ: NARI) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference scheduled for January 11th at 2:15 PM PT. The management team's presentation will be available for 30 days via a live audio webcast on the company's website.
Inari focuses on medical devices aimed at treating venous diseases. Their products include the ClotTriever and FlowTriever systems, both 510(k)-cleared by the FDA, designed for non-surgical removal of clots in patients with conditions like deep vein thrombosis and pulmonary embolism.
Inari Medical, Inc. (NASDAQ: NARI), a company dedicated to developing medical devices for venous diseases, announced its participation in the Canaccord Genuity MedTech Forum on November 17, 2022, at the Westin NY Grand Central Hotel. The company specializes in catheter-based mechanical thrombectomy devices, including the ClotTriever and FlowTriever systems, designed for non-surgical removal of clots from blood vessels. Both products are FDA 510(k)-cleared and CE marked, targeting deep vein thrombosis and pulmonary embolism.
Inari Medical, Inc. (NASDAQ: NARI) reported third-quarter 2022 revenue of $96.2 million, a 32% increase from the same quarter in 2021. The growth is attributed to U.S. commercial expansion, increased procedure adoption, and the launch of two new products, Protrieve and InThrill. Despite a net loss of $10.2 million for the quarter, the company ended with $319.2 million in cash and investments. Inari has raised its full-year revenue guidance to a range of $373 million to $375 million.
Inari Medical, Inc. (NASDAQ: NARI) announced positive results from the 500-patient CLOUT registry, confirming the ClotTriever system's effectiveness for treating deep vein thrombosis (DVT). Over 90% of patients achieved complete thrombus extraction with only one serious device-related adverse event. The analysis also revealed that ClotTriever had nearly double the thrombus clearance compared to standard treatment methods, along with a 13% reduction in post-thrombotic syndrome. Inari aims to establish ClotTriever as a standard of care for DVT and pulmonary embolism (PE) patients.
Inari Medical, Inc. (NASDAQ: NARI) plans to release its third quarter 2022 financial results on November 2, 2022. The medical device company, focused on treating venous diseases, will host a conference call at 1:30 p.m. PT to discuss its results and recent highlights. Inari's product line includes the ClotTriever and FlowTriever systems, designed for the non-surgical removal of clots from large vessels, addressing conditions like deep vein thrombosis and pulmonary embolism. Interested parties can access the call via telephone or through their investor relations website.
Inari Medical (NASDAQ: NARI) announced positive results from the 800-patient FLASH registry, presented at the 2022 TCT conference. The study, evaluating the FlowTriever system in treating pulmonary embolism (PE), reported a low major adverse event rate of 1.8% and 30-day all-cause mortality of just 0.8%. The findings underscore FlowTriever's strong safety profile and clinical effectiveness, suggesting it may enhance PE treatment outcomes. Inari aims to continue developing high-quality evidence through ongoing studies like the FLAME registry and PEERLESS trial.
Inari Medical, Inc. (NASDAQ: NARI) announced its first Analyst and Investor Day scheduled for September 15, 2022, at its headquarters in Irvine, California. The event will involve a comprehensive update on the company’s business progress and future plans via a webcast set to begin at 9 a.m. Pacific Time. Participation is open to interested stakeholders, who can pre-register through a provided link. Additionally, a replay of the presentation will be available for 90 days on the company's Investor Relations website.
Inari Medical, Inc. (NASDAQ: NARI) announced the presentation of three new data sets from pivotal clinical studies at the 2022 TCT and VEINS conferences. The FLASH registry will showcase results from 800 patients treated with the FlowTriever system, focusing on safety and clinical outcomes, presented on September 18. The CLOUT registry results involving 500 patients will be shared on October 30-31, evaluating the ClotTriever system's effectiveness. A comparison of CLOUT data with ATTRACT outcomes will also be highlighted. These studies aim to refine the treatment standards for venous thromboembolism (VTE).
Inari Medical (NASDAQ: NARI) announced the upcoming enrollment of the DEFIANCE trial, a randomized controlled study aimed at assessing the effectiveness of the ClotTriever System for treating iliofemoral deep vein thrombosis (DVT) compared to traditional anticoagulation therapy. This trial will involve 300 patients across 60 centers globally. DEFIANCE is expected to set new treatment standards and reduce post-thrombotic syndrome risks. It follows the PEERLESS trial, further bolstering Inari's commitment to pioneering clinical research in vascular treatments.
Inari Medical, Inc. (NASDAQ: NARI) announced its participation in two upcoming investor conferences. The first is the Wells Fargo Healthcare Conference on September 9, 2022, at 8:35 a.m. Eastern Time in Boston, MA, featuring a fireside chat. The second is the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 8:10 a.m. Eastern Time in New York, NY, also a fireside chat. Interested parties can access live audio webcasts through the company’s website.
FAQ
What is the current stock price of Inari Medical (NARI)?
What is the market cap of Inari Medical (NARI)?
What does Inari Medical, Inc. specialize in?
What are the key products in Inari Medical's portfolio?
Where does Inari Medical generate most of its revenue?
What recent clinical study has Inari Medical announced?
How did Inari Medical perform financially in the fourth quarter of 2023?
What is Inari Medical's approach to innovation?
Who should investors contact for more information?
What legal actions has Inari Medical recently taken?
What are Inari Medical's guiding principles?
How can interested parties access Inari Medical's live events?
